Table 3. Risk factors for acquiring resistance to OFX during MDR TB treatment, 161 patients, in Arkhangelsk, Russia, 2005–2010*.
| Variable† | Total | Acquired ofloxacin resistance, no. (%) |
p value‡ | |
|---|---|---|---|---|
| Yes | No | |||
| Enrollment cohort | ||||
| 2005–2006 | 64 | 0 (0) | 64 (100) | 0.08 |
| 2007–2008 | 97 | 6 (6.2) | 91 (93.8) | |
| Body mass index <18.5 at MDR TB diagnosis | ||||
| Yes | 35 | 4 (11.4) | 31 (88.6) | 0.02 |
| No | 126 | 2 (1.6) | 124 (98.4) | |
| Hospitalized at time of enrollment | ||||
| Yes | 159 | 5 (3.1) | 154 (96.9) | 0.07 |
| No | 2 | 1 (50) | 1 (50) | |
| Ever received MOX during current episode | ||||
| Yes | 26 | 4 (15.4) | 22 (84.6) | 0.007 |
| No | 135 | 2 (1.5) | 133 (98.5) | |
| Changed FQ during current episode | ||||
| Yes | 10 | 2 (20) | 8 (80) | 0.05 |
| No | 151 | 4 (2.6) | 147 (97.4) | |
| Ever received a third-line drug during episode | ||||
| Yes | 79 | 6 (7.6) | 73 (92.4) | 0.01 |
| No | 82 | 0 (0) | 82 (100) | |
*FQ, fluoroquinolone; OFX, ofloxacin; MDR TB, multidrug-resistant tuberculosis; MOX, moxifloxicin. †Certain variables were tested for association but omitted from table because results were not statistically significant at α = 0.1. ‡Fisher exact test.